Navigation Links
Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
Date:3/25/2009

CALGARY, March 25 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) today announced the completion of patient enrolment in its U.K. clinical trial to evaluate the anti-tumour effects of intravenous administration of REOLYSIN(R) in combination with gemcitabine (Gemzar(R)) in patients with advanced cancers including breast, and head and neck. The principal investigators are Dr. Johann de Bono of The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, U.K., and Professor Jeff Evans of the University of Glasgow, Scotland.

A total of 15 patients were enrolled in the trial. Of the ten patients evaluable for response, two patients (breast and nasopharyngeal) had partial responses (PRs) and five patients had SD (stable disease) for 4-8 cycles, for a total disease control rate (CR (Complete response)+PR +SD) of 70%.

"The results to date using this treatment combination in late-stage cancer patients indicate that further studies using this drug combination are warranted," said Dr. Brad Thompson, President and CEO of Oncolytics. "We plan to initiate further studies in the U.S. using a modified dosage regime of REOLYSIN and the commonly used U.S. dosage of gemcitabine (800 mg/m(2)) in patients with advanced or metastatic pancreatic cancer in partnership with the Cancer Therapy & Research Center at The University of Texas Health Science Center in San Antonio, (CTRC at UTHSCSA)."

The U.K. trial (REO 009) is an open-label, dose-escalating, non-randomized study of REOLYSIN given intravenously with gemcitabine every three weeks. Gemcitabine (1000 mg/m(2)) was administered to patients in combination with escalating dosages of REOLYSIN intravenously.

Eligible patients included those who had been diagnosed with advanced or metastatic solid tumours including pancreatic, l
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
2. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
3. Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
4. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
5. Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
6. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North America
7. Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent
8. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
9. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
10. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
11. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Cambridge Semantics, the leading provider of smart ... 2014 was a record-breaking year across the board for the ... Smart Data Platform and our Smart Data solutions, our customers ... data which led to record growth for the company in ...
(Date:1/22/2015)... 22, 2015 Crystal Diagnostics (CDx) Xpress System, ... has received AOAC-PTM Certifications for the six non-O157 Shiga toxin-producing ... collectively referred to as STEC or the “Big-6”) as well ... unit (cfu) per 325 g of raw ground beef and ...
(Date:1/22/2015)... 2015 Dr. Greg Leyer of UAS Labs ... Natural Supplements Pre-Conference seminar on probiotics in San Diego, CA. ... continuing education conference for health care professionals. This year’s pre-conference ... of probiotics in health. Dr. Leyer spoke about the emerging ...
(Date:1/22/2015)... NJ (PRWEB) January 22, 2015 ... technologies such as the Bioruptor® and complete solutions ... system for chromatin immunoprecipitation, alleviating the need for ... and controls needed for ChIP of histones or ...
Breaking Biology Technology:Cambridge Semantics Announces Record Results for 2014 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2
... MARCY L,ETOILE, France , May 21 ... entered into a partnership to commercialize a mass spectrometry ... work with Shimadzu and their subsidiary, Kratos Analytical, to ... integration into the microbiology laboratory workflow. This new solution ...
... , May 21 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, ... (REOLYSIN(R)) are available on the American Society of Clinical Oncology (ASCO) website ... . The research is scheduled to be presented at the ASCO 2010 ... , , , ...
... Ill., May 21 Abbott (NYSE: ... to acquire full ownership of Piramal,s Healthcare Solutions business (Domestic ... an up-front payment of $2.12 billion , plus ... Abbott the No. 1 position in the Indian pharmaceutical market. ...
Cached Biology Technology:Shimadzu and bioMerieux Enter into Partnership for Mass Spectrometry Applications in Microbiology 2Shimadzu and bioMerieux Enter into Partnership for Mass Spectrometry Applications in Microbiology 3Shimadzu and bioMerieux Enter into Partnership for Mass Spectrometry Applications in Microbiology 4Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting 2Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting 3Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting 4Abbott to Become No. 1 Pharmaceutical Company in India with Acquisition of Piramal's Healthcare Solutions Business 2Abbott to Become No. 1 Pharmaceutical Company in India with Acquisition of Piramal's Healthcare Solutions Business 3Abbott to Become No. 1 Pharmaceutical Company in India with Acquisition of Piramal's Healthcare Solutions Business 4Abbott to Become No. 1 Pharmaceutical Company in India with Acquisition of Piramal's Healthcare Solutions Business 5Abbott to Become No. 1 Pharmaceutical Company in India with Acquisition of Piramal's Healthcare Solutions Business 6
(Date:12/15/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) ... Recognition Market 2015-2019" report to their offering. ... recognition is a technology used for the identification of ... of a person such as nose, jaw edges, mouth, ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences International (DSI), ... released a new series of digital telemetry implants ... researchers. M series, part of the PhysioTel™ Digital ... best possible physiologic data when incorporating functional endpoints ...
(Date:12/10/2014)... , Dec. 9, 2014 CIE San Diego has launched ... connective tissue that enhances care coordination among social service and ... earned a second $1 million grant from the Alliance Healthcare ... and; will be recognized as a "Live Well San Diego" ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... KAN. -- Research from a Kansas State University professor ... injury or to study neurological disorders. Mark Weiss, ... for spinal cord injury or diseases such as Parkinson,s ... therapy and regenerative medicine -- a type of research ...
... Wales and the United States have collaborated to complete ... energy crop called miscanthus. The results published in ... PLoS One provide a significant breakthrough towards ... results from the long-term collaboration between energy crop company ...
... study by Indiana University researchers confirm anecdotal evidence that ... to female orgasm. While the findings are ... of its association with exercises for core abdominal muscles, ... Herbenick, co-director of the Center for Sexual Health Promotion ...
Cached Biology News:Genetic research develops tools for studying diseases, improving regenerative treatment 2First complete full genetic map of promising energy crop 2First complete full genetic map of promising energy crop 3Study: Exercise can lead to female orgasm, sexual pleasure 2Study: Exercise can lead to female orgasm, sexual pleasure 3
... 50g of purified RNA samples for RT-PCR and ... of the advantages and applications you expect from ... can be used for enzymatic applications such as ... optimised for the stabilization of aqueous RNA samples ...
... PYREX Fernbach-style culture flasks have triple baffles ... bottom to achieve maximal oxygen transfer to ... marking spot., A wide range of optional ... Polypropylene colored caps for ease of ...
... template is designed to allow kanamycin/neomycin ... It combines a prokaryotic promoter (gb2) ... E.coli with a eukaryotic promoter (PGK) ... cells. The prokaryotic promoter gb2 is ...
... FRT-PGK-gb2-neo-FRT template is designed to ... cells. The FRT-PGK-gb2-neo-FRT template encodes the ... promoter (gb2) for expression of kanamycin resistance ... promoter (PGK) for expression of neomycin resistance ...
Biology Products: